ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

By Karen Tkach Tuzman, Associate Editor

Dec 8, 2020 | 2:06 AM GMT

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological